Xbrane Biopharma: Still A Hidden Gem
Research Update
2022-11-03
08:15
Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci by the European Commission, bringing the Q1 2023 launch in Europe closer. 2023 will be a pivotal year for Xbrane, and the share price is likely to follow, we judge.
FE
FT
Filip Einarsson
Fredrik Thor
Disclosures and disclaimers